Carregant...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
ABV-press
2021-09-01
|
| Col·lecció: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| Matèries: | |
| Accés en línia: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|